β-Amyloid

Shop By

15 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Gamma-secretase inhibitor

    BMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis.
  2. Gamma-secretase inhibitor

    RO4929097 is an orally bioavailable, small-molecule gamma secretase (GS) inhibitor with an IC50 of 4 nM.
  3. Gamma-secretase inhibitor

    MK-0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated.
  4. Amyloid-β production inhibitor

    gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor. gamma-Secretase Modulators is useful for Alzheimer's disease.
  5. amyloid β42 inhibitor

    Ro 90-7501 is an inhibitor of amyloid β42 (Aβ42) fibril assembly; reduces Aβ42-induced toxicity (EC50 = 2 μM).
  6. β-amyloid (Aβ) inhibitor

    ALZ-801 is an oral, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation for Alzheimer's disease (AD). ALZ-801 is a prodrug of tramiprosate with improved pharmacokinetic properties and gastrointestinal tolerability.
  7. glutaminyl cyclase inhibitor

    Glutaminyl Cyclase Inhibitor 2 is a glutaminyl cyclase inhibitor with an IC50 of 1.23 μM.
  8. glutaminyl cyclase inhibitor

    Glutaminyl Cyclase Inhibitor 1 is a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM.
  9. Oligomeric aggregation inhibitor

    Anle138b is an oligomeric aggregation inhibitor. Anle138b is an oligomer modulator for neurodegenerative diseases such Parkinson's disease.
  10. GC inhibitor

    Glutaminyl Cyclase Inhibitor 3 (compound 212 ), a designed anti-Alzheimer??s compound, is a potent human Glutaminyl Cyclase (GC) inhibitor, with an IC50 of 4.5 nM.
  11. RAGE inhibitor

    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer??s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
  12. Aβ-aggregation inhibitor

    MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
  13. Aβ-ABAD inhibitor

    Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.

  14. Aβ Inhibitor

    K 01-162 (K162) binds and destabilizes AβO (β-amyloid), with an EC50 of 80 nM.
  15. AChE and BuChE inhibitor

    TAE-1 is an inhibitor of amyloid-β fibril formation and aggregation. TAE-1 inhibits cholinesterases AChE and BuChE with IC50 of 0.3 μM and 3.9 μM, respectively.

15 Items

per page
Set Descending Direction